pharma · Idiopathic Hypersomnia · Prader-Willi Syndrome · HRMY
Harmony Biosciences Holdings
Harmony Biosciences is a pharma organization headquartered in Plymouth Meeting, USA. It trades on NYSE under ticker HRMY. Primary therapeutic focus areas include Idiopathic Hypersomnia, Prader-Willi Syndrome, Hair Thinni
630 W. Germantown Pike, Suite 220, Plymouth Meeting, PA 19462, US HQ
2017 Founded
332 Employees
Public company Type
HRMY · NYSE Ticker
Company details
- Status
- Public
- HQ
- 630 W. Germantown Pike, Suite 220, Plymouth Meeting, PA 19462, US
- Founded
- 2017
- Employees
- 332
- Programs
- 21
- Drugs
- 14
- Patents
- 6
ZYN002
Phase 2 · small molecule · 22Q11.2 Deletion Syndrome
ZYN002 for 22Q11.2 Deletion Syndrome is a Phase 2 program (small_molecule) at Harmony Biosciences Holdings with 1 ClinicalTrials.gov record(s).
Internal code ZYN2-CL-031
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Harmony Biosciences Holdings
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- 22Q11.2 Deletion Syndrome
- Status
- completed
- Trials
- 1